Analog Devices and Flex LNG break records while Sisram experiences a regional decline
Communications chips carried Analog Devices to record profits, while Flex LNG achieved a strong increase in charter earnings. Sisram Medical, however, experienced a 21.6 per cent drop in North American sales.
Economics & Markets··Evening
What boosted Analog Devices' profits?
Analog Devices' revenue reached 4.022 billion dollars in the quarter ended August 1, exceeding the previous year by 40 per cent. The primary drivers of growth were an 84 per cent increase in communications and a 53 per cent rise in the industrial segment. Industrial demand constituted the portion equating to 49 per cent of revenue, at 1.972 billion dollars; communications reached 655 million dollars. The adjusted gross margin was 72.5 per cent, and the operating margin was 50.0 per cent. The company returned 1.692 billion dollars to its shareholders this quarter. Automotive showed a 16 per cent increase.[1]
How did Flex LNG increase its charter earnings?
Flex LNG's vessel operating revenues grew from 80.5 million dollars in the first quarter to 106.8 million dollars. This increase occurred due to the time charter equivalent rate rising from 65,729 dollars to 86,119 dollars a day. Net profit reached 44.9 million dollars from 19.5 million dollars, and earnings per share went up to 0.83 dollars from 0.36 dollars. Adjusted EBITDA climbed from 53.2 million dollars to 79.0 million dollars. The company holds 397 million dollars in cash assets and has no debt maturing before 2029. Full-year revenue is targeted between 345 million dollars and 370 million dollars.[2]
Which regions challenged Sisram Medical?
While Sisram Medical's half-year revenue increased by 3.6 per cent to 171.4 million dollars, North American sales dropped 21.6 per cent, settling at 44.4 million dollars. This decline was offset by sales outside North America growing by 16.7 per cent to 127.0 million dollars. Revenues in the Asia-Pacific region rose 19.1 per cent to 78.4 million dollars, and in Europe by 12.1 per cent to 26.7 million dollars. Injectables revenue saw a 54.2 per cent increase, reaching 22.2 million dollars. The gross margin fell from 60.0 per cent to 56.7 per cent, and net profit decreased from 9.0 million dollars to 1.1 million dollars.[3]
